Objectives To retrospectively review the oncologic outcomes of docetaxel-based
chemotherapy in Japanese men with metastatic castration-resistant prostate cancer …

Objectives The objective of this study was to evaluate the significance of docetaxel-based
chemotherapy in elderly Japanese men with metastatic castration-resistant prostate cancer …

Background Guidelines define docetaxel as a first‐line therapeutic option for metastatic
castration‐resistant prostate cancer (mCRPC). However, the role of docetaxel in non …

Background A low-dose chemotherapy consisting of docetaxel, estramustine and
dexamethasone was investigated for its beneficial effect and feasibility in Japanese patients …

Purpose With the emergence of various novel therapies including new generation taxane
and androgen-targeted therapies, the optimal sequence of systemic treatment in metastatic …

Objective To clarify the risk factors and develop a refined risk-stratification model to help in
the appropriate selection of docetaxel chemotherapy in patients with castration-resistant …

Purpose For patients with metastatic castration-resistant prostatic cancer (mCRPC),
docetaxel plus prednisone leads to superior survival and a higher response rate compared …

Background: Treatment with docetaxel in combination with prednisone is the standard first-
line treatment in patients with metastatic castration-resistant prostate cancer (mCRPC). For …

Purpose The purpose of the study was to define clinical factors for successful treatment
response and re-exposure to docetaxel in metastatic castration-resistant prostate cancer …

Background The aim of this study was to investigate the efficacy and toxicity of docetaxel-
based chemotherapy, and to investigate pretreatment factors that can predict overall survival …